Table 3.
Associations between pathways and prognosis in ICCA patients
| Pathway | p-Value | |
|---|---|---|
| PFS | OS | |
| p53 signaling pathway | 0.683091 | 1 |
| PD-L1 expression and PD-1 checkpoint pathway in cancer | 0.214193 | 0.08201 |
| T cell receptor signaling pathway | 1 | 0.066393 |
| Cell cycle | 0.683091 | 1 |
| Natural killer cell mediated cytotoxicity | 1 | 0.066393 |
| Platinum drug resistance | 0.619297 | 0.771926 |
| Insulin signaling pathway | 0.567628 | 0.182287 |
| mTOR signaling pathway | 1 | 0.333949 |
| JAK-STAT signaling pathway | 0.396144 | 0.226256 |
| EGFR tyrosine kinase inhibitor resistance | 0.619297 | 0.333949 |
| Wnt signaling pathway | 0.683091 | 1 |
| Proteoglycans in cancer | 0.706082 | 0.825863 |
| Rap1 signaling pathway | 0.619297 | 0.333949 |
| Ras signaling pathway | 0.298698 | 0.544329 |
| Signaling pathways regulating pluripotency of stem cells | 0.298698 | 0.544329 |
| MAPK signaling pathway | 0.362355 | 0.333949 |
| FoxO signaling pathway | 0.665006 | 0.544329 |
| Hepatocellular carcinoma | 0.100348 | 1 |
| PI3K-Akt signaling pathway | 0.706082 | 0.825863 |
| MicroRNAs in cancer | 0.706082 | 0.825863 |